<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OTO</journal-id>
<journal-id journal-id-type="hwp">spoto</journal-id>
<journal-title>Otolaryngology–Head and Neck Surgery</journal-title>
<issn pub-type="ppub">0194-5998</issn>
<issn pub-type="epub">1097-6817</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0194599811434003</article-id>
<article-id pub-id-type="publisher-id">10.1177_0194599811434003</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Laryngology and Neurolaryngology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Preliminary Report of Vocal Fold Augmentation with Cross-Linked Porcine Collagen</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Chi-Te</given-names></name>
<degrees>MD, MPH</degrees>
<xref ref-type="aff" rid="aff1-0194599811434003">1</xref>
<xref ref-type="aff" rid="aff2-0194599811434003">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Liao</surname><given-names>Li-Jen</given-names></name>
<degrees>MD, MPH</degrees>
<xref ref-type="aff" rid="aff1-0194599811434003">1</xref>
<xref ref-type="aff" rid="aff2-0194599811434003">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Huang</surname><given-names>Tsung-Wei</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0194599811434003">1</xref>
<xref ref-type="aff" rid="aff2-0194599811434003">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Cheng</surname><given-names>Po-Wen</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0194599811434003">1</xref>
<xref ref-type="aff" rid="aff2-0194599811434003">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0194599811434003"><label>1</label>Department of Otolaryngology, Far Eastern Memorial Hospital, Taipei, Taiwan</aff>
<aff id="aff2-0194599811434003"><label>2</label>Oriental Institute of Technology, Taipei, Taiwan</aff>
<author-notes>
<corresp id="corresp1-0194599811434003">Po-Wen Cheng, MD, PhD, Department of Otolaryngology, Far Eastern Memorial Hospital, 21, Section 2, Nan-Ya South Rd, Pan Chiao, Taipei, Taiwan Email: <email>powenjapan@yahoo.com.tw</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>146</volume>
<issue>4</issue>
<fpage>606</fpage>
<lpage>610</lpage>
<history>
<date date-type="received">
<day>26</day>
<month>8</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>25</day>
<month>11</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>12</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© American Academy of Otolaryngology—Head and Neck Surgery Foundation 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Official journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation</copyright-holder>
</permissions>
<abstract>
<p><italic>Objective</italic>. To evaluate the short-term outcomes of using cross-linked porcine collagen for vocal fold augmentation.</p>
<p><italic>Study Design</italic>. Case series with planned data collection.</p>
<p><italic>Setting</italic>. Tertiary referral hospital.</p>
<p><italic>Subjects and Methods</italic>. Twenty consecutive patients of unilateral vocal fold paralysis (UVFP) were recruited, including 10 males and 10 females. All the subjects received videolaryngostroboscopic (VLS) evaluation for the glottic closure pattern, perceptual grading using the GRB scale (grade, roughness, breathiness), acoustic analysis, maximal phonation time (MPT), and Voice Handicap Index (VHI) questionnaire. Purified telopeptide-free, glutaraldehyde cross-linked porcine collagen was injected under local anesthesia with fiberscopic guidance.</p>
<p><italic>Results</italic>. Treatment outcomes were evaluated 3 months after the injection. Fifteen (75%) of 20 patients reported complete resolution of symptoms, whereas the other 5 (25%) patients had substantial improvements. The median score of perceptual analysis of voice quality showed significant improvements from G2/R2/B2 to G1/R1/B0 (<italic>P</italic> &lt; .001). Glottic closure pattern under stroboscopy had improved from “predominantly open” before the procedure to a “half-open and half-close” pattern after the procedure (<italic>P</italic> &lt; .001). Acoustic analysis demonstrated significant improvements of jitter and normalized noise energy (<italic>P</italic> &lt; .05). Maximal phonation time revealed a significant improvement from 7.5 ± 3.2 seconds to 13.1 ± 3.9 seconds (<italic>P</italic> &lt; .01). The VHI had also decreased from 53 ± 25 points to 27 ± 20 points (<italic>P</italic> &lt; .01). No patients had serious adverse events during the follow-up period.</p>
<p><italic>Conclusion</italic>. This case series demonstrated that porcine collagen may be a suitable material for temporary vocal fold augmentation.</p>
</abstract>
<kwd-group>
<kwd>vocal fold</kwd>
<kwd>injection laryngoplasty</kwd>
<kwd>porcine collagen</kwd>
<kwd>vocal fold paralysis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Vocal fold augmentation was first introduced by Dr Bruening in 1911 to correct the glottic gap of unilateral vocal fold paralysis. Although the initial trial was unsuccessful, further application of Teflon paste has made this procedure familiar among otolaryngologists.<sup><xref ref-type="bibr" rid="bibr1-0194599811434003">1</xref></sup> However, the popularity of Teflon injections has declined following the identification of adverse tissue reaction such as giant cell foreign body granuloma.<sup><xref ref-type="bibr" rid="bibr2-0194599811434003">2</xref></sup> Various injection materials have since been developed, including bovine collagen,<sup><xref ref-type="bibr" rid="bibr3-0194599811434003">3</xref></sup> homologous collagen,<sup><xref ref-type="bibr" rid="bibr4-0194599811434003">4</xref></sup> and autologous fat.<sup><xref ref-type="bibr" rid="bibr5-0194599811434003">5</xref></sup> Recently, synthetic materials have been introduced for vocal fold augmentation, such as hyaluronic acid,<sup><xref ref-type="bibr" rid="bibr6-0194599811434003">6</xref></sup> calcium hydroxylapatite,<sup><xref ref-type="bibr" rid="bibr7-0194599811434003">7</xref></sup> polymethyl methacrylate microsphere,<sup><xref ref-type="bibr" rid="bibr8-0194599811434003">8</xref></sup> and polyacrylamide hydrogel.<sup><xref ref-type="bibr" rid="bibr9-0194599811434003">9</xref></sup></p>
<p>Of these materials, bovine collagen has accumulated the most clinical experience in treating vocal fold paralysis, atrophy, and scarring.<sup><xref ref-type="bibr" rid="bibr10-0194599811434003">10</xref>,<xref ref-type="bibr" rid="bibr11-0194599811434003">11</xref></sup> However, hypersensivity to bovine collagen and potential transmission of bovine spongiform encephalopathy have lowered its clinical preference as an injection material. Because porcine collagen is genetically more similar to human, it has a better biocompatibility and a lower rate of allergic reactions as compared with bovine collagen, thereby reducing the need for routine preoperative dermal tests.<sup><xref ref-type="bibr" rid="bibr12-0194599811434003">12</xref></sup></p>
<p>To date, porcine collagen has not been used for vocal fold injections despite its successful experiences in aesthetic surgery.<sup><xref ref-type="bibr" rid="bibr13-0194599811434003">13</xref></sup> Therefore, this case series intends to document the short-term outcomes of this novel material for vocal fold augmentation.</p>
<sec id="section1-0194599811434003" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section2-0194599811434003">
<title>Patient Recruitment</title>
<p>Between April and December 2010, 20 consecutive patients (10 males and 10 females) with unilateral vocal fold paralysis (UVFP) were referred to a tertiary teaching hospital. All subjects received a thorough physical examination; the UVFP diagnosis was based on the finding of the videolaryngostroboscopic (VLS) evaluation. For UVFP subjects without an underlying cause, we performed contrast-enhanced computed tomographic (CT) scans from skull base to chest/mediastinum to rule out the occurrence of occult neoplasm along the route of the recurrent laryngeal nerve.<sup><xref ref-type="bibr" rid="bibr14-0194599811434003">14</xref></sup> No subject had a medical history of collagen vascular disease or previous allergic reactions to animal/collagen products. All the patients signed an informed consent, and this study was approved by the Far Eastern Memorial Hospital (FEMH) Research Ethics Review Committee.</p>
</sec>
<sec id="section3-0194599811434003">
<title>Videolaryngostroboscopy</title>
<p>Each patient received VLS evaluation during the clinical visits before and after the procedure. This was performed by instructing the patient to phonate a sustained “ee” sound with habitual pitch and intensity, using a 70° rigid endoscope (Model 2706 CA; KARL STORZ, Tuttlingen, Germany) and a 3-chip CCD camera (Model 20222120; KARL STORZ). Each session of the VLS test was digitally recorded onto a portable hard disk via computerized video processor (NHX-B10; Grass Valley, Inc, Nevada City, California). Two otolaryngologists evaluated the closure pattern of vocal folds using a stroboscopy research instrument.<sup><xref ref-type="bibr" rid="bibr15-0194599811434003">15</xref></sup> They reached consensus on the rating value, which was further numerated on a 4-point scale for easier statistical computation (1 = predominantly closed; 2 = closed/open; 3 = predominantly open; 4 = always open).<sup><xref ref-type="bibr" rid="bibr15-0194599811434003">15</xref></sup></p>
</sec>
<sec id="section4-0194599811434003">
<title>Perceptual and Acoustic Analysis of Voice Quality</title>
<p>Two independent clinicians evaluated voice quality using a 4-point GRB scale (grade, roughness, breathiness).<sup><xref ref-type="bibr" rid="bibr16-0194599811434003">16</xref></sup> Voice recordings were obtained using a unidirectional microphone placed 10 cm in front of a subject’s mouth. A 3-second sample of a sustained “ee” sound was analyzed using Dr. Speech software, version 4 (Tiger DRS, Inc, Seattle, Washington). Analytical parameters included jitter (%), shimmer (%), and normalized noise energy (dB). Maximal phonation time (MPT) was measured by 3 consecutive trials.</p>
</sec>
<sec id="section5-0194599811434003">
<title>Injection Material</title>
<p>Purified telopeptide-free, glutaraldehyde cross-linked porcine collagen was derived from specific pathogen-free porcine dermal tissue (Sunmax Collagen Implant I-Plus, Taipei, Taiwan). Each syringe contained 35 mg/mL purified cross-linked collagen, primarily composed of type I atelocollagen. Because significant allergic reactions to porcine collagen did not occur in the previous study,<sup><xref ref-type="bibr" rid="bibr12-0194599811434003">12</xref></sup> we did not perform a routine skin test in this series.</p>
</sec>
<sec id="section6-0194599811434003">
<title>Vocal Fold Augmentation</title>
<p>Vocal fold augmentation was performed after adequate local anesthesia of the nose, pharynx, and larynx, including a local spray of 10% Xylocaine over the pharynx, tonsil, vallecula, and epiglottis, followed by “laryngeal gargling” using 2% Xylocaine solution.<sup><xref ref-type="bibr" rid="bibr17-0194599811434003">17</xref></sup> An experienced doctor operated on the transnasal digital fiberscope for glottis visualization (VNL-1590STi; Kaypentax, Lincoln Park, New Jersey). Then, a 25-gauge, 1.5-inch needle was passed just above the thyroid notch. The technique for the thyrohyoid approach of vocal fold augmentation was described elsewhere.<sup><xref ref-type="bibr" rid="bibr18-0194599811434003">18</xref></sup> Injection locations were (1) lateral to the vocal process and (2) mid-third of the vocal fold, at the level of deep lamina propria (between the vocal ligament and vocalis muscle). The required amount of augmentation was based on individual need, usually around 0.5 to 1.0 mL. To compensate for early absorption of the water component of injectables, approximately 25% overcorrection was performed. The vocal fold should be convex at the conclusion of the procedures.<sup><xref ref-type="bibr" rid="bibr5-0194599811434003">5</xref>,<xref ref-type="bibr" rid="bibr10-0194599811434003">10</xref></sup> Subsequently, all the patients underwent voice rest for 3 days to prevent leakage or local hematoma.</p>
</sec>
<sec id="section7-0194599811434003">
<title>Outcome Evaluation and Statistical Analysis</title>
<p>Outcome measurements were conducted at 3 months after the procedure, including (1) perceptual analysis of voice quality using the GRB scale; (2) patients’ subjective rating, categorized as complete resolution of symptoms, substantial improvement, or no improvement or worse; (3) acoustic analysis; (4) MPT; (5) stroboscopic evaluation of vocal fold closure pattern; and (6) Voice Handicap Index (VHI) questionnaire.<sup><xref ref-type="bibr" rid="bibr19-0194599811434003">19</xref></sup> Subsequently, MPT and VHI were measured again at 6 months after the injections. Paired <italic>t</italic> test was applied to compare continuous parameters (ie, MPT, VHI, and acoustic analysis). For ordinal data, such as perceptual and stroboscopic ratings, Wilcoxon signed-rank test was used to evaluate the differences before and after the procedure. A <italic>P</italic> value &lt;.05 was considered statistically significant. All statistical analyses were conducted with SPSS software, version 18.0 (SPSS, Inc, an IBM Company, Chicago, Illinois).</p>
</sec>
</sec>
<sec id="section8-0194599811434003" sec-type="results">
<title>Results</title>
<p>Age distribution of the 20 recruited patients was 32 to 89 years (median, 66 years). The left vocal fold was involved in 17 patients, whereas the other 3 had their right fold involved. The recognized etiologies of vocal fold paralysis were thyroid cancer in 4 patients, lung cancer in 3, esophageal surgery in 3, cerebral vascular event in 2, Parkinsonism in 1, and neck trauma in 1. For the remaining 6 subjects, a clear etiology could not be determined after subsequent CT scan and, hence, the cause was categorized as “idiopathic.” Subjective treatment outcomes measured at 3 months after the injection showed complete resolution of symptoms in 15 (75%) patients and substantial improvement in the other 5 (25%) patients. <xref ref-type="fig" rid="fig1-0194599811434003"><bold>Figure 1</bold></xref> demonstrates serial pictures of VLS before and 3 months after the treatment in a case of left vocal fold paralysis after cardiovascular surgery.</p>
<fig id="fig1-0194599811434003" position="float">
<label>Figure 1.</label>
<caption><p>Videolaryngoscopy in a 42-year-old woman with left-side vocal fold paralysis after surgery for a dissecting aortic aneurysm, showing a bowed left vocal fold during inspiration (a) and a moderate glottic gap during phonation (b). Three months after vocal fold augmentation using cross-linked porcine collagen, videolaryngoscopy demonstrates a straightened and augmented left vocal fold during inspiration (c) and a complete glottic closure during phonation (d).</p></caption>
<graphic xlink:href="10.1177_0194599811434003-fig1.tif"/>
</fig>
<p>Perceptual analysis of voice quality showed that the median preinjection scores were G2/R2/B2 in comparison with postinjection scores of G1/R1/B0, demonstrating significant improvements (<italic>P</italic> &lt; .01, Wilcoxon signed-rank test). Stroboscopic evaluation indicated that the pattern of glottic closure was “predominantly open” before the procedure (median: 3 points), which significantly improved to a “half-open and half-closed” pattern 3 months after the procedure (median: 2 points; <italic>P</italic> &lt; .001, Wilcoxon signed-rank test). Furthermore, acoustic analysis of voice quality using computer software demonstrated significant improvements in both jitter and normalized noise energy (<xref ref-type="table" rid="table1-0194599811434003"><bold>Table 1</bold></xref>; <italic>P</italic> ≤ .001, paired <italic>t</italic> test). Although the value of shimmer improved after the treatment, it did not achieve statistical significance (<italic>P</italic> = .053, paired <italic>t</italic> test).</p>
<table-wrap id="table1-0194599811434003" position="float">
<label>Table 1.</label>
<caption><p>Acoustic Analysis before and 3 Months after the Treatment in 20 Patients with Unilateral Vocal Fold Paralysis</p></caption>
<graphic alternate-form-of="table1-0194599811434003" xlink:href="10.1177_0194599811434003-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Parameters</th>
<th align="center">Before</th>
<th align="center">3 Months</th>
<th align="center">Change</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn2-0194599811434003">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>Jitter, %</td>
<td>0.66 (0.57)</td>
<td>0.24 (0.18)</td>
<td>0.42 (0.33)</td>
<td>.001</td>
</tr>
<tr>
<td>Shimmer, %</td>
<td>4.32 (3.87)</td>
<td>2.88 (2.83)</td>
<td>1.44 (1.31)</td>
<td>.053</td>
</tr>
<tr>
<td>NNE, dB</td>
<td>−5.31 (−3.09)</td>
<td>−11.41 (−12.28)</td>
<td>6.10 (4.88)</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0194599811434003">
<p>Data are expressed as mean (median) value. NNE, normalized noise energy.</p>
</fn>
<fn id="table-fn2-0194599811434003">
<label>a</label>
<p>Paired <italic>t</italic> test.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Results of MPT revealed a significant improvement from 7.5 ± 3.2 seconds (mean ± standard deviation) before the injection to 13.1 ± 3.9 seconds 3 months after the injection (<xref ref-type="fig" rid="fig2-0194599811434003"><bold>Figure 2</bold></xref>; <italic>P</italic> &lt; .01, paired <italic>t</italic> test). The improvement remained significant at 6 months (12.6 ± 3.2 seconds, <italic>P</italic> &lt; .01, compared with baseline; <xref ref-type="fig" rid="fig2-0194599811434003"><bold>Figure 2</bold></xref>). On the other hand, subjective outcome evaluation using VHI demonstrated a significant decrease from 53 ± 25 points to 27 ± 20 points 3 months after the procedure (<xref ref-type="fig" rid="fig3-0194599811434003">Figure 3</xref>; <italic>P</italic> &lt; .01, paired <italic>t</italic> test). The VHI scores were 25 ± 17 points at 6 months, which also revealed a sustained improvement (<italic>P</italic> &lt; .01, compared with baseline; <xref ref-type="fig" rid="fig3-0194599811434003"><bold>Figure 3</bold></xref>).</p>
<fig id="fig2-0194599811434003" position="float">
<label>Figure 2.</label>
<caption><p>Maximal phonation time (MPT) before, 3 months, and 6 months after the treatment, demonstrating a significant improvement from 7.5 seconds to 13.1 and 12.6 seconds, respectively (mean value, <italic>P</italic> &lt; .01, paired <italic>t</italic> test).</p></caption>
<graphic xlink:href="10.1177_0194599811434003-fig2.tif"/>
</fig>
<fig id="fig3-0194599811434003" position="float">
<label>Figure 3.</label>
<caption><p>Illustration of treatment outcome using the Voice Handicap Index (VHI) questionnaire. The mean score decreased from 53 points before the treatment to 27 points 3 months after the treatment (<italic>P</italic> &lt; .01, paired <italic>t</italic> test). Repeated measurement at 6 months revealed a sustained improvement (mean: 25 points, <italic>P</italic> &lt; .01, compared with baseline, paired <italic>t</italic> test).</p></caption>
<graphic xlink:href="10.1177_0194599811434003-fig3.tif"/>
</fig>
<p>During the follow-up period, no patient developed allergic reactions to porcine collagen. Eight patients reported increased laryngeal secretion, and 3 encountered mild vocal fold hematoma, both of which resolved spontaneously within 2 weeks. On the other hand, 1 patient had undercorrection of the glottic gap, whereas another patient had early absorption of implant material in the third month. We did not experience any case of superficial injection into Reinke space, vocal fold granuloma formation, or stiffened vocal folds in this series.</p>
</sec>
<sec id="section9-0194599811434003" sec-type="discussion">
<title>Discussion</title>
<p>Collagen-based injection materials have been widely used in vocal fold augmentation since the 1980s,<sup><xref ref-type="bibr" rid="bibr3-0194599811434003">3</xref></sup> and the proposed indications include unilateral vocal fold paralysis, glottic insufficiency, and vocal fold scarring.<sup><xref ref-type="bibr" rid="bibr11-0194599811434003">11</xref></sup> Injectable collagen primarily acts as a soft tissue filler but may also stimulate fibroblasts of the recipient site, resulting in some degree of host collagen deposition.<sup><xref ref-type="bibr" rid="bibr20-0194599811434003">20</xref></sup> Although the cross-linked form of bovine collagen (Zyplast; Allergan, Irvine, California) has decreased the hypersensitivity rate and lengthened the duration of clinical effectiveness,<sup><xref ref-type="bibr" rid="bibr21-0194599811434003">21</xref>,<xref ref-type="bibr" rid="bibr22-0194599811434003">22</xref></sup> preinjection skin tests are still required. Although the use of micronized homologous dermis (Cymetra; LifeCell, Branchburg, New Jersey) in vocal fold augmentation has been proposed with documented efficacy and safety,<sup><xref ref-type="bibr" rid="bibr23-0194599811434003">23</xref>,<xref ref-type="bibr" rid="bibr24-0194599811434003">24</xref></sup> this dry-powered material requires additional time for rehydrating process before usage. Some patients may also have psychological concerns regarding the cadaveric origin of skin tissue.</p>
<p>In addition to these collagen-based products, porcine collagen has been widely used as a safe and effective tissue filler.<sup><xref ref-type="bibr" rid="bibr25-0194599811434003">25</xref></sup> Histopathological studies have demonstrated a well-tolerated host-implant interaction without evidence of local inflammation or other adverse events.<sup><xref ref-type="bibr" rid="bibr26-0194599811434003">26</xref></sup> According to the previous literature, none of the 519 subjects developed significant allergic reactions after the intradermal injection of porcine collagen, and hence a preinjection skin test appears unnecessary.<sup><xref ref-type="bibr" rid="bibr12-0194599811434003">12</xref></sup> Except for the material used in this study, there are several other commercially available products of porcine collagen, such as Evolence (ColBar Life-Science, Ltd, Herzliya, Israel), Permacol (Tissue Science Laboratories, Swillington, UK), and Dermicol (Evolence Breeze; Ortho Dermatologics, Skillman, New Jersey). All these materials are readily injectable, which saves preparation time before the procedure. Although we cannot be certain that pigs are absolutely free of the transmission risk of viral or prion disease, to our best knowledge, no such adverse event has been reported in the literature. Therefore, this study intends to examine whether porcine collagen can be a potential candidate material for vocal fold augmentation.</p>
<p>We demonstrated that vocal fold augmentation with porcine collagen is a practical treatment option for UVFP patients. Because these patients may have a severe underlying disease or be recovering from a major operation, other treatment modalities requiring general anesthesia such as autologous fat injection may not be suitable. Alternatively, all patients tolerated the procedure well under local anesthesia without developing any postinjection airway compromise or allergic reaction.</p>
<p>This study applied a multidimensional protocol to evaluate the functional results of vocal fold augmentation.<sup><xref ref-type="bibr" rid="bibr19-0194599811434003">19</xref></sup> First, subjective ratings of treatment outcomes showed that 75% (n = 15) of the patients reported complete resolution of clinical symptoms, whereas 25% (n = 5) of the patients stated substantial remission. Second, the VHI decreased from 53 ± 25 points to 27 ± 20 and 25 ±17 points at 3 and 6 months, respectively (<xref ref-type="fig" rid="fig3-0194599811434003"><bold>Figure 3</bold></xref>; <italic>P</italic> &lt; .01). Third, the phonatory efficiency test using MPT showed a marked improvement from 7.5 ± 3.2 seconds to 13.1 ± 3.9 and 12.6 ± 3.2 seconds at 3 and 6 months, respectively (<xref ref-type="fig" rid="fig2-0194599811434003"><bold>Figure 2</bold></xref>; <italic>P</italic> &lt; .01). Thus, both MPT and VHI evaluations demonstrated a significant and sustained change up to 6 months after the procedure. Fourth, perceptual analysis of voice quality using the GRB scale revealed significant improvements from G2/R2/B2 to G1/R1/B0 (<italic>P</italic> &lt; .001). Fifth, stroboscopic assessment also demonstrated a much improved closure pattern of vocal folds after the procedure (<italic>P</italic> &lt; .001). Finally, acoustic analysis using various measurement parameters revealed significant improvements in voice quality (<xref ref-type="table" rid="table1-0194599811434003"><bold>Table 1</bold></xref>; <italic>P</italic> ≤ .001). In sum, this pilot series documented beneficial clinical outcomes of porcine collagen in treating UVFP.</p>
<p>In this series, none of the patients developed allergic reactions to porcine collagen, nor did they show clinical signs of foreign body reactions. These results indicated a good biocompatibility of this material, which may be comparable with modern synthetic injection materials.<sup><xref ref-type="bibr" rid="bibr6-0194599811434003">6</xref>-<xref ref-type="bibr" rid="bibr9-0194599811434003">9</xref></sup> Minor adverse effects occurring after the procedure could be managed conservatively. Vocal fold hematoma was most likely due to needle injury during the procedure or strenuous coughing afterward, which usually resolved spontaneously within 2 weeks and did not lead to focal scar formation. Furthermore, none of the patients encountered material misinjection into the superficial lamina propria, nor did they develop focal stiffening of vocal folds due to uneven augmentation. These preferable outcomes could be attributed to the better visibility of the needle tip<sup><xref ref-type="bibr" rid="bibr18-0194599811434003">18</xref></sup> and the lower extrusion force of porcine collagen,<sup><xref ref-type="bibr" rid="bibr26-0194599811434003">26</xref></sup> which helped the surgeon to maintain a smooth and steady injection process. However, because the material was injected transluminally, the case of undercorrection might have resulted from extrusion of injection material through the needle hole.</p>
<p>In conclusion, this case series demonstrated that porcine collagen may be a suitable material for temporary vocal fold augmentation. A subsequent long-term follow-up study is warranted to document the sustained duration of this material, as well as to delineate the likelihood of long-term complications. Meanwhile, larger sample sizes are required before confident safety profiles can be stated. On the basis of our preliminary results, further studies may proceed to compare the therapeutic effectiveness between porcine collagen and other injection materials.</p>
</sec>
<sec id="section10-0194599811434003">
<title>Author Contributions</title>
<p><bold>Chi-Te Wang</bold>, conception and design, analysis and interpretation of data; <bold>Li-Jen Liao</bold>, acquisition of data; <bold>Tsung-Wei Huang</bold>, acquisition of data; <bold>Po-Wen Cheng</bold>, conception and design, analysis and interpretation of data.</p>
</sec>
<sec id="section11-0194599811434003">
<title>Disclosures</title>
<p><bold>Competing interests:</bold> None.</p>
<p><bold>Sponsorships:</bold> None.</p>
<p><bold>Funding source:</bold> This work was supported by research grants (FEMH-99-C-028 and FEMH-96-D-004) from Far Eastern Memorial Hospital, Taipei, Taiwan.</p>
</sec>
</body>
<back>
<ack>
<p>We thank Anthony Lee for manuscript editing.</p>
</ack>
<fn-group>
<fn fn-type="presented-at">
<p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p>
<p>This article was presented at the 4th World Voice Congress; September 6-9, 2010; Seoul, Korea</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0194599811434003">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dedo</surname><given-names>HH</given-names></name>
<name><surname>Urrea</surname><given-names>RD</given-names></name>
<name><surname>Lawson</surname><given-names>L</given-names></name>
</person-group>. <article-title>Intracordal injection of Teflon in the treatment of 135 patients with dysphonia</article-title>. <source>Ann Otol Rhinol Laryngol</source>. <year>1973</year>;<volume>82</volume>:<fpage>661</fpage>-<lpage>667</lpage>.</citation>
</ref>
<ref id="bibr2-0194599811434003">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dedo</surname><given-names>HH</given-names></name>
<name><surname>Carlsoo</surname><given-names>B</given-names></name>
</person-group>. <article-title>Histologic evaluation of Teflon granulomas of human vocal cords: a light and electron microscopic study</article-title>. <source>Acta Otolaryngol</source>. <year>1982</year>;<volume>93</volume>:<fpage>475</fpage>-<lpage>484</lpage>.</citation>
</ref>
<ref id="bibr3-0194599811434003">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ford</surname><given-names>CN</given-names></name>
<name><surname>Bless</surname><given-names>DM</given-names></name>
</person-group>. <article-title>Clinical experience with injectable collagen for vocal fold augmentation</article-title>. <source>Laryngoscope</source>. <year>1986</year>;<volume>96</volume>:<fpage>863</fpage>-<lpage>869</lpage>.</citation>
</ref>
<ref id="bibr4-0194599811434003">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Remacle</surname><given-names>M</given-names></name>
<name><surname>Lawson</surname><given-names>G</given-names></name>
<name><surname>Keghian</surname><given-names>J</given-names></name>
<name><surname>Jamart</surname><given-names>J</given-names></name>
</person-group>. <article-title>Use of injectable autologous collagen for correcting glottic gaps: initial results</article-title>. <source>J Voice</source>. <year>1999</year>;<volume>13</volume>:<fpage>280</fpage>-<lpage>288</lpage>.</citation>
</ref>
<ref id="bibr5-0194599811434003">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hsiung</surname><given-names>MW</given-names></name>
<name><surname>Woo</surname><given-names>P</given-names></name>
<name><surname>Minasian</surname><given-names>A</given-names></name>
<name><surname>Schaefer Mojica</surname><given-names>J</given-names></name>
</person-group>. <article-title>Fat augmentation for glottic insufficiency</article-title>. <source>Laryngoscope</source>. <year>2000</year>;<volume>110</volume>:<fpage>1026</fpage>-<lpage>1033</lpage>.</citation>
</ref>
<ref id="bibr6-0194599811434003">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hertegard</surname><given-names>S</given-names></name>
<name><surname>Hallen</surname><given-names>L</given-names></name>
<name><surname>Laurent</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Cross-linked hyaluronan used as augmentation substance for treatment of glottal insufficiency: safety aspects and vocal fold function</article-title>. <source>Laryngoscope</source>. <year>2002</year>;<volume>112</volume>:<fpage>2211</fpage>-<lpage>2219</lpage>.</citation>
</ref>
<ref id="bibr7-0194599811434003">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosen</surname><given-names>CA</given-names></name>
<name><surname>Gartner-Schmidt</surname><given-names>J</given-names></name>
<name><surname>Casiano</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>Vocal fold augmentation with calcium hydroxylapatite: twelve-month report</article-title>. <source>Laryngoscope</source>. <year>2009</year>;<volume>119</volume>:<fpage>1033</fpage>-<lpage>1041</lpage>.</citation>
</ref>
<ref id="bibr8-0194599811434003">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Min</surname><given-names>JY</given-names></name>
<name><surname>Hong</surname><given-names>SD</given-names></name>
<name><surname>Kim</surname><given-names>K</given-names></name>
<name><surname>Son</surname><given-names>YI</given-names></name>
</person-group>. <article-title>Long-term results of Artecoll injection laryngoplasty for patients with unilateral vocal fold motion impairment: safety and clinical efficacy</article-title>. <source>Arch Otolaryngol Head Neck Surg</source>. <year>2008</year>;<volume>134</volume>:<fpage>490</fpage>-<lpage>496</lpage>.</citation>
</ref>
<ref id="bibr9-0194599811434003">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>SW</given-names></name>
<name><surname>Son</surname><given-names>YI</given-names></name>
<name><surname>Kim</surname><given-names>CH</given-names></name>
<name><surname>Lee</surname><given-names>JY</given-names></name>
<name><surname>Kim</surname><given-names>SC</given-names></name>
<name><surname>Koh</surname><given-names>YW</given-names></name>
</person-group>. <article-title>Voice outcomes of polyacrylamide hydrogel injection laryngoplasty</article-title>. <source>Laryngoscope</source>. <year>2007</year>;<volume>117</volume>:<fpage>1871</fpage>-<lpage>1875</lpage>.</citation>
</ref>
<ref id="bibr10-0194599811434003">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Remacle</surname><given-names>M</given-names></name>
<name><surname>Dujardin</surname><given-names>JM</given-names></name>
<name><surname>Lawson</surname><given-names>G</given-names></name>
</person-group>. <article-title>Treatment of vocal fold immobility by glutaraldehyde–cross-linked collagen injection: long-term results</article-title>. <source>Ann Otol Rhinol Laryngol</source>. <year>1995</year>;<volume>104</volume>:<fpage>437</fpage>-<lpage>441</lpage>.</citation>
</ref>
<ref id="bibr11-0194599811434003">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ford</surname><given-names>CN</given-names></name>
<name><surname>Bless</surname><given-names>DM</given-names></name>
<name><surname>Loftus</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Role of injectable collagen in the treatment of glottic insufficiency: a study of 119 patients</article-title>. <source>Ann Otol Rhinol Laryngol</source>. <year>1992</year>;<volume>101</volume>:<fpage>237</fpage>-<lpage>247</lpage>.</citation>
</ref>
<ref id="bibr12-0194599811434003">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shoshani</surname><given-names>D</given-names></name>
<name><surname>Markovitz</surname><given-names>E</given-names></name>
<name><surname>Cohen</surname><given-names>Y</given-names></name>
<name><surname>Heremans</surname><given-names>A</given-names></name>
<name><surname>Goldlust</surname><given-names>A</given-names></name>
</person-group>. <article-title>Skin test hypersensitivity study of a cross-linked, porcine collagen implant for aesthetic surgery</article-title>. <source>Dermatol Surg</source>. <year>2007</year>;<volume>33</volume>(<supplement>suppl 2</supplement>):<fpage>S152</fpage>-<lpage>S158</lpage>.</citation>
</ref>
<ref id="bibr13-0194599811434003">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saray</surname><given-names>A</given-names></name>
</person-group>. <article-title>Porcine dermal collagen (Permacol) for facial contour augmentation: preliminary report</article-title>. <source>Aesthetic Plast Surg</source>. <year>2003</year>;<volume>27</volume>: <fpage>368</fpage>-<lpage>375</lpage>.</citation>
</ref>
<ref id="bibr14-0194599811434003">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Richardson</surname><given-names>BE</given-names></name>
<name><surname>Bastian</surname><given-names>RW</given-names></name>
</person-group>. <article-title>Clinical evaluation of vocal fold paralysis</article-title>. <source>Otolaryngol Clin North Am</source>. <year>2004</year>;<volume>37</volume>:<fpage>45</fpage>-<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr15-0194599811434003">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosen</surname><given-names>CA</given-names></name>
</person-group>. <article-title>Stroboscopy as a research instrument: development of a perceptual evaluation tool</article-title>. <source>Laryngoscope</source>. <year>2005</year>;<volume>115</volume>:<fpage>423</fpage>-<lpage>428</lpage>.</citation>
</ref>
<ref id="bibr16-0194599811434003">
<label>16.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Hirano</surname><given-names>M</given-names></name>
</person-group>. <source>Clinical Examination of the Voice</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Springer Verlag</publisher-name>; <year>1981</year>.</citation>
</ref>
<ref id="bibr17-0194599811434003">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Woo</surname><given-names>P</given-names></name>
</person-group>. <article-title>Office-based laryngeal procedures</article-title>. <source>Otolaryngol Clin North Am</source>. <year>2006</year>;<volume>39</volume>:<fpage>111</fpage>-<lpage>133</lpage>.</citation>
</ref>
<ref id="bibr18-0194599811434003">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Amin</surname><given-names>MR</given-names></name>
</person-group>. <article-title>Thyrohyoid approach for vocal fold augmentation</article-title>. <source>Ann Otol Rhinol Laryngol</source>. <year>2006</year>;<volume>115</volume>:<fpage>699</fpage>-<lpage>702</lpage>.</citation>
</ref>
<ref id="bibr19-0194599811434003">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dejonckere</surname><given-names>PH</given-names></name>
</person-group>. <article-title>Clinical implementation of a multidimensional basic protocol for assessing functional results of voice therapy: a preliminary study</article-title>. <source>Rev Laryngol Otol Rhinol (Bord)</source>. <year>2000</year>;<volume>121</volume>:<fpage>311</fpage>-<lpage>313</lpage>.</citation>
</ref>
<ref id="bibr20-0194599811434003">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ford</surname><given-names>CN</given-names></name>
<name><surname>Martin</surname><given-names>DW</given-names></name>
<name><surname>Warner</surname><given-names>TF</given-names></name>
</person-group>. <article-title>Injectable collagen in laryngeal rehabilitation</article-title>. <source>Laryngoscope</source>. <year>1984</year>;<volume>94</volume>:<fpage>513</fpage>-<lpage>518</lpage>.</citation>
</ref>
<ref id="bibr21-0194599811434003">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Remacle</surname><given-names>M</given-names></name>
<name><surname>Marbaix</surname><given-names>E</given-names></name>
<name><surname>Hamoir</surname><given-names>M</given-names></name>
<name><surname>Bertrand</surname><given-names>B</given-names></name>
<name><surname>van den Eeckhaut</surname><given-names>J</given-names></name>
</person-group>. <article-title>Correction of glottic insufficiency by collagen injection</article-title>. <source>Ann Otol Rhinol Laryngol</source>. <year>1990</year>;<volume>99</volume>:<fpage>438</fpage>-<lpage>444</lpage>.</citation>
</ref>
<ref id="bibr22-0194599811434003">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ford</surname><given-names>CN</given-names></name>
<name><surname>Bless</surname><given-names>DM</given-names></name>
</person-group>. <article-title>Selected problems treated by vocal fold injection of collagen</article-title>. <source>Am J Otolaryngol</source>. <year>1993</year>;<volume>14</volume>:<fpage>257</fpage>-<lpage>261</lpage>.</citation>
</ref>
<ref id="bibr23-0194599811434003">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Remacle</surname><given-names>M</given-names></name>
<name><surname>Lawson</surname><given-names>G</given-names></name>
</person-group>. <article-title>Results with collagen injection into the vocal folds for medialization</article-title>. <source>Curr Opin Otolaryngol Head Neck Surg</source>. <year>2007</year>;<volume>15</volume>:<fpage>148</fpage>-<lpage>152</lpage>.</citation>
</ref>
<ref id="bibr24-0194599811434003">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tan</surname><given-names>M</given-names></name>
<name><surname>Woo</surname><given-names>P</given-names></name>
</person-group>. <article-title>Injection laryngoplasty with micronized dermis: a 10-year experience with 381 injections in 344 patients</article-title>. <source>Laryngoscope</source>. <year>2010</year>;<volume>120</volume>:<fpage>2460</fpage>-<lpage>2466</lpage>.</citation>
</ref>
<ref id="bibr25-0194599811434003">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gurney</surname><given-names>TA</given-names></name>
<name><surname>Kim</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Applications of porcine dermal collagen (ENDURAGen) in facial plastic surgery</article-title>. <source>Facial Plast Surg Clin North Am</source>. <year>2007</year>;<volume>15</volume>:<fpage>113</fpage>-<lpage>121</lpage>, viii.</citation>
</ref>
<ref id="bibr26-0194599811434003">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lorenc</surname><given-names>ZP</given-names></name>
<name><surname>Nir</surname><given-names>E</given-names></name>
<name><surname>Azachi</surname><given-names>M</given-names></name>
</person-group>. <article-title>Characterization of physical properties and histologic evaluation of injectable Dermicol-p35 porcine-collagen dermal filler</article-title>. <source>Plast Reconstr Surg</source>. <year>2010</year>;<volume>125</volume>: <fpage>1805</fpage>-<lpage>1813</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>